Long-term nebivolol administration reduces renal fibrosis and prevents endothelial dysfunction in rats with hypertension induced by renal mass reduction

Journal of Hypertension

Volumn 25, Issue 12, 2007, Pages 2486-2496

  Pires, María J ^a,b   Rodríguez Peña, Ana B ^a   Arévalo, Miguel ^a   Cenador, Begoña ^a   Evangelista, Stefano ^c   Esteller, Alejandro ^a   Sánchez Rodríguez, Ángel ^d   Colaço, Aura ^b   López Novoa, José M ^a  

^a UNIVERSITY OF SALAMANCA   (Spain)

^b UNIVERSITY OF TRÁS OS MONTES AND ALTO DOURO   (Portugal)

^c Menarini Ricerche SpA   (Italy)

^d HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

Author keywords

Beta blockers; Endothelial dysfunction; Hypertension; Nitric oxide; Oxidative stress; Rats; Renal fibrosis

Indexed keywords

8 ISOPROSTAGLANDIN F2 ALPHA; ACROLEIN; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOLOGICAL MARKER; COLLAGEN TYPE 1; LYSINE; NEBIVOLOL; THIOBARBITURIC ACID REACTIVE SUBSTANCE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIHYPERTENSIVE ACTIVITY; ANTIHYPERTENSIVE THERAPY; ARTERIAL PRESSURE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; ENDOTHELIAL DYSFUNCTION; GLOMERULOPATHY; HYPERTENSION; KIDNEY FIBROSIS; KIDNEY INJURY; KIDNEY MASS; LONG TERM CARE; MALE; NEPHRECTOMY; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZATION; RAT; RENAL PROTECTION; TREATMENT OUTCOME; URINARY EXCRETION;

EID: 35848944112     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/HJH.0b013e3282efeecb     Document Type: Article

References (58)

1. Remuzzi G, Ruggenenti P, Benigni A. Understanding the nature of renal disease progression. Kidney Int 1997; 51:2-15.
2. Anderson S, Meyer TW, Rennke H, Brenner BM. Control of glomerular hypertension limits glomerular injury in rats with reduced renal mass. J Clin Invest 1985; 76:612-619.
3. Brenner BM. Nephron adaptation to renal injury or ablation. Am J Physiol 1985; 249:F324-F337.
4. Klahr S, Morrissey J. L-arginine as a therapeutic tool in kidney disease. Semin Nephrol 2004; 24:389-394.
5. Benigni A, Zoja C, Noris M, Corna D, Benedetti G, Bruzzi I, et al. Renoprotection by nitric oxide donor and lisinopril in the remnant kidney model. Am J Kidney Dis 1999; 33:746-753.
6. Janssens WJ, Van De Water A, Xhonneux R, Reneman RS, Van Nueten JM, Janssen PA. Nebivolol is devoid of sympathomimetic activity. Eur J Pharmacol 1989; 159:89-95.
7. Brixius K, Bundkirchen A, Bolck B, Mehlhorn U, Schwinger RH. Nebivolol, bucindolol, metoprolol and carvedilol are devoid of intrinsic sympathomimetic activity in human myocardium. Br J Pharmacol 2001; 133:1330-1338.
8. Gao YS, Nagao T, Bond RA, Janssens WJ, Vanhoutte PM. Nebivolol induces endothelium-dependent relaxations of canine coronary arteries. J Cardiovasc Pharmacol 1991; 17:964-969.
9. 125I]iodocyanopindolol binding studies. Eur J Pharmacol 2003; 460:19-26.
10. Ignarro LJ. Experimental evidence of nitric oxide-dependent vasodilatory activity of nebivolol, a third generation β-blocker. Blood Press 2004; 13:3-17.
11. Altwegg LA, D'Uscio LV, Barandier C, Cosentino F, Yang Z, Lüscher TF. Nebivolol induces NO-mediated relaxations of rat small resistance but not of large elastic arteries. J Cardiovasc Pharmacol 2000; 36:316-320.
12. Falciani M, Rinaldi B, D'Agostino B, Mazzeo F, Rossi S, Nobili B, et al. Effects of nebivolol on human platelet aggregation. J Cardiovasc Pharmacol 2001; 38:922-929.
13. Bowman AJ, Chen C, Ford GA. Nitric oxide mediated venodilator effect of nebivolol. Br J Clin Pharmacol 1994; 38:199-204.
14. Cockroft JR, Chowienczyk PJ, Brett SE, Chen CPL-H, Dupont AG, Van Nueten L, et al. Nebivolol vasodilates human forearm vasculature: evidence for an L-arginine/NO-dependent mechanism. J Pharmacol Exp Ther 1995; 274:1067-1071.
15. Tzemos N, Lim PO, McDonald TM. Nebivolol reverses endothelial dysfunction in essential hypertension: a randomised, double-blind, crossover study. Circulation 2001; 104:511-514.
16. Fratta Pasini A, Garbin U, Nava MC, Stranieri C, Davoli A, Sawamura T, et al. Nebivolol decreases oxidative stress in essential hypertensive patients and increases nitric oxide by reducing its oxidative inactivation. J Hypertens 2005; 23:589-596.
17. Xhonneux R, Wouters L, Reneman RS, Janssen PA. The L-enantiomer of nebivolol potentiates the blood pressure lowering effect of the D-enantiomer. Eur J Pharmacol 1990; 181:261-265.
18. Guerrero E, Voces F, Ardanaz N, Montero MJ, Arevalo M, Sevilla MA. Long-term treatment with nebivolol improves arterial reactivity and reduces ventricular hypertrophy in spontaneously hypertensive rats. J Cardiovasc Pharmacol 2003; 42:348-355.
19. Sacco G, Evangelista S, Criscuoli M, Goso C, Bigioni M, Binaschi M, et al. Involvement of nitric oxide in both central and peripheral haemodynamic effect of D/L-nebivolol and its enantiomers in rats. Eur J Pharmacol 2005; 511:167-174.
20. Kalinowski L, Dobrucki LW, Szczepanska-Konkel M, Jankowski M, Martyniec L, Angielski S, Malinski T. Third-generation beta-blockers stimulate nitric oxide release from endothelial cells through ATP efflux: a novel mechanism for antihypertensive action. Circulation 2003; 107:2747-2752.
21. Georgescu A, Pluteanu F, Flonta ML, Badila E, Dorobantu M, Popov D. The cellular mechanisms involved in the vasodilator effect of nebivolol on the renal artery. Eur J Pharmacol 2005; 508:159-166.
22. Kakoki M, Hirata Y, Hayakawa H, Nishimatsu H, Suzuki Y, Nagata D, et al. Effects of vasodilatory beta-adrenoceptor antagonists on endothelium-derived nitric oxide release in rat kidney. Hypertension 1999; 33:467-471.
23. Rodriguez-Pena A, Prieto M, Duwel A, Rivas JV, Eleno N, Perez-Barriocanal F, et al. Up-regulation of endoglin, a TGF-beta-binding protein, in rats with experimental renal fibrosis induced by renal mass reduction. Nephrol Dial Transplant 2001; 16 (Suppl 1):34-39.
24. López-Farré A, Bernabeu F, Gómez-Garre DN, Ramón y Cajal S, Braquet P, López-Novoa JM. Platelet activating factor antagonist treatment protects against postischemic acute renal failure in rats. J Pharmacol Exp Ther 1990; 253:328-333.
25. Morales AI, Vicente-Sanchez C, Sandoval JM, Egido J, Mayoral P, Arevalo MA, et al. Protective effect of quercetin on experimental chronic cadmium nephrotoxicity in rats is based on its antioxidant properties. Food Chem Toxicol 2006; 44:2092-2100.
26. Flores O, Arévalo M, Gallego B, Hidalgo F, Vidal S, López-Novoa JM. Beneficial effect of the long-term treatment with the combination of an ACE-inhibitor and calcium channel blocker on renal injury in rats with 5/6 nephrectomy. Exp Nephrol 1998; 6:39-49.
27. Schanstra JP, Neau E, Drogoz P, Arevalo Gomez MA, Lopez Novoa JM, Calise D, et al. In vivo bradykinin B2 receptor activation reduces renal fibrosis. J Clin Invest 2002; 110:371-379.
28. Rodriguez-Pena A, Eleno N, Duwell A, Arevalo M, Perez-Barriocanal F, Flores O, et al. Endoglin upregulation during experimental renal interstitial fibrosis in mice. Hypertension 2002; 40:713-720.
29. Jerkic M, Rivas-Elena JV, Prieto M, Carron R, Sanz-Rodriguez F, Perez-Barriocanal F, et al. Endoglin regulates nitric oxide-dependent vasodilatation. FASEB J 2004; 18:609-611.
30. Perez-Rivero G, Ruiz-Torres MP, Rivas-Elena JV, Jerkic M, Diez-Marques ML, Lopez-Novoa JM, et al. Mice deficient in telomerase activity develop hypertension because of an excess of endothelin production. Circulation 2006; 114:309-317.
31. Zanchetti A. Clinical pharmacodynamics of nebivolol: new evidence of nitric oxide-mediated vasodilating activity and peculiar haemodynamic properties in hypertensive patients. Blood Press Suppl 2004; 1:17-32.
32. Fortepiani LA, Ortiz MC, Atucha NM, Garcia-Estan J. Nebivolol ameliorates nitric oxide deficient hypertension. Sci World J 2002; 2:1676-1684.
33. Guerrero EI, Ardanaz N, Sevilla MA, Arevalo MA, Montero MJ. Cardiovascular effects of nebivolol in spontaneously hypertensive rats persist after treatment withdrawal. J Hypertens 2006; 24:151-158.
34. Tamaki K, Okuda S. Role of TGF-beta in the progression of renal fibrosis. Contrib Nephrol 2003; 139:44-65.
35. Peters H, Ruckert M, Gaedeke J, Liefeldt L, Ketteler M, Sharma AM, Neumayer HH. Angiotensin-converting enzyme inhibition but not beta-adrenergic blockade limits transforming growth factor-beta overexpression in acute normotensive antithy1 glomerulonephritis. J Hypertens 2003; 21:771-780.
36. Aiello S, Noris M, Todeschini M, Zappella S, Foglieni C, Benigni A, et al. Renal and systemic nitric oxide synthesis in rats with renal mass reduction. Kidney Int 1997; 52:171-181.
37. Ashab I, Peer G, Blum M, Wollman Y, Chernihovsky T, Hassner A, et al. Oral administration of L-arginine and captopril in rats prevents chronic renal failure by nitric oxide production. Kidney Int 1995; 47:1515-1521.
38. Schmidt RJ, Yokota S, Tracy TS, Sorkin MI, Baylis C. Nitric oxide production is low in end-stage renal disease patients on peritoneal dialysis. Am J Physiol 1999; 276:F794-F797.
39. Schmidt RJ, Baylis C. Total nitric oxide production is low in patients with chronic renal disease. Kidney Int 2000; 58:1261-1266.
40. Wang Y, Kramer S, Loof T, Martini S, Kron S, Kawachi H, et al. Stimulation of soluble guanylate cyclase slows progression in antithy1-induced chronic glomerulosclerosis. Kidney Int 2005; 68:47-61.
41. Erdely A, Wagner L, Muller V, Szabo A, Baylis C. Protection of Wistar Furth rats from chronic renal disease is associated with maintained renal nitric oxide synthase. J Am Soc Nephrol 2003; 14:2526-2533.
42. Ying L, Flamant M, Vandermeersch S, Boffa JJ, Chatziantoniou C, Dussaule JC, Chansel D. Renal effects of omapatrilat and captopril in salt-loaded, nitric oxide-deficient rats. Hypertension 2003; 42:937-944.
43. Zatz R, Baylis C. Chronic nitric oxide inhibition model six years on. Hypertension 1998; 32:958-964.
44. Hahn S, Krieg RJ Jr, Hisano S, Chan W, Kuemmerle NB, Saborio P, Chan JC. Vitamin E suppresses oxidative stress and glomerulosclerosis in rat remnant kidney. Pediatr Nephrol 1999; 13:195-198.
45. Hahn S, Kuemmerle NB, Chan W, Hisano S, Saborio P, Krieg RJ Jr, Chan JC. Glomerulosclerosis in the remnant kidney rat is modulated by dietary alpha-tocopherol. J Am Soc Nephrol 1998; 9:2089-2095.
46. Hasdan G, Benchetrit S, Rashid G, Green J, Bernheim J, Rathaus M. Endothelial dysfunction and hypertension in 5/6 nephrectomized rats are mediated by vascular superoxide. Kidney Int 2002; 61:586-590.
47. Chade AR, Rodriguez-Porcel M, Herrmann J, Zhu X, Grande JP, Napoli C, et al. Antioxidant intervention blunts renal injury in experimental renovascular disease. J Am Soc Nephrol 2004; 15:958-966.
48. De Groot AA, Mathy MJ, van Zwieten PA, Peters SL. Antioxidant activity of nebivolol in the rat aorta. J Cardiovasc Pharmacol 2004; 43:148-153.
49. Mollnau H, Schulz E, Daiber A, Baldus S, Oelze M, August M, et al. Nebivolol prevents vascular NOS III uncoupling in experimental hyperlipidemia and inhibits NADPH oxidase activity in inflammatory cells. Arterioscler Thromb Vasc Biol 2003; 23:615-621.
50. Pechter U, Aunapuu M, Riispere Z, Vihalemm T, Kullissaar T, Zilmer K, et al. Oxidative stress status in kidney tissue after losartan and atenolol treatment in experimental renal failure. Nephron Exp Nephrol 2004; 97:33-37.
51. Lawson JA, Rokach J, FitzGerald GA. Isoprostanes: Formation, analysis and use as indices of lipid peroxidation in vivo. J Biol Chem 1999; 274:24441-24444.
52. Reckelhoff J, Zhang H, Srivastava K, Roberts LJ II, Morrow JD, Romero JC. Subpressor doses of Ang II increase plasma F2- isoprostanes in rats. Hypertension 2000; 35:476-479.
53. Ortiz MC, Manriquez MC, Romero JC, Juncos LA. Antioxidants block angiotensin II-induced increases in blood pressure and endothelin. Hypertension 2001; 38:655-659.
54. Yura T, Fukunaga M, Khan R, Nassar GN, Badr KF, Montero A. Free radical-generated F2-isoprostane stimulates cell proliferation and endothelin-1 expression in endothelial cells. Kidney Int 1999; 56:471-478.
55. Zou H, Kato A, Miyaji T, Yasuda H, Fujigaki Y, Yamamoto T, et al. Urinary marker for oxidative stress in kidneys in cisplatin-induced acute renal failure in rats. Nephrol Dial Transplant 2006; 21:616-623.
56. Uchida K. Current status of acrolein as a lipid peroxidation product. Trends Cardiovasc Med 1999; 9:109-113.
57. Hamada Y, Miyata S, Nii-Kono T, Kitazawa R, Kitazawa S, Higo S, et al. Overexpression of thioredoxin1 in transgenic mice suppresses development of diabetic nephropathy. Nephrol Dial Transplant 2007; 22:1547-1557.
58. Nakagawa N, Hasebe N, Sumitomo K, Fujino T, Fukuzawa J, Hirayama T, Kikuchi K. An oral adsorbent, AST-120, suppresses oxidative stress in uremic rats. Am J Nephrol 2006; 26:455-461.